Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00965497 · ClinicalTrials.gov registry record · Phase 3
Escitalopram (Lexapro) for Depression MS or ALS
A Phase 3 study, sponsored by University of South Carolina.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT00965497: Completed Phase 3 study, sponsored by University of South Carolina.
NCT00965497 is a Phase 3 study that has completed, run by University of South Carolina. The registered enrollment target is 13 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00965497, a Phase 3 study, has completed, sponsored by University of South Carolina.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.
Primary Outcome
Hamilton Depression Rating Scale-17 (HAM-D) is a 17-item observer rated scale that measures depressive symptoms. Items are rated 0 (no symptoms)-4 ( most severe symptoms. Possible minimum and maximum scores range is 0-50. total score indications: 0-7 = Normal; 8-13 = Mild Depression; 14-18 = Moderate Depression; 19-22 = Severe Depression and ≥ 23 = Very Severe Depression.
Interventions
- DRUG escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
What the finished NCT00965497 record still lists
NCT00965497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which escitalopram is the first listed.
NCT00965497 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00965497 about?
NCT00965497 is a clinical study titled "Escitalopram (Lexapro) for Depression MS or ALS". The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.
What is the current status of trial NCT00965497?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2009-07. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00965497?
The interventions under investigation include: escitalopram (DRUG).
Who is sponsoring clinical trial NCT00965497?
This trial is sponsored by University of South Carolina, which has 157 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00965497's enrollment target sits among peer trials
13 1984th of 2000 higher than 17 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia